ClinicalTrials.gg
RecruitingNCT06364670Updated Apr 15, 2024

Application of Machine Learning Based on fNIRS in Predicting Acupuncture's Efficacy in Treating Tinnitus

An interventional study of acupuncture in Tinnitus, sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tinnitus with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Tinnitus · China.

Planned enrollment
Largest of 27
500 · median 120
Started
2024
with 5 others
No phase
27 of 32
16 open now
Primary completion
2026-08
later than 6 of 17 live
Registered
17th of 32
by date
Lead sponsor
3 of 32
The Third Affiliated hospital of Zhejiang Chinese Medical University

Among the 32 studies in Tinnitus with a site in China, this one has the largest planned enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2024, is one of 27 with no phase, reaches primary completion later than 6 of the 17 other live ones, and was the 17th registered.

Tinnitus

446 studies on the registry are indexed under Tinnitus; 98 are open to participants now.

Browse Tinnitus studies →

Open to participants now

18 of the 32 studies in Tinnitus with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Tinnitus studies recruiting now, 21 (43%) set no upper age limit and 18 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tinnitus with a site in China, or all of them as a file.
02

Study summary

This trial aims to use machine learning to analyze fNIRS imaging data of specific brain regions of tinnitus patients, thereby constructing a predictive model of the clinical efficacy of acupuncture for SNT.

Read the detailed description

This study will recruit 500 subjects with tinnitus. Functional near-infrared spectroscopy (fNIRS) will be employed to examine specific brain regions, and the corresponding fNIRS imaging data from all detection channels will be extracted. Subsequently, the subjects will undergo a course of acupuncture treatment. Based on the recovery status of tinnitus at the conclusion of the acupuncture course, all subjects will be categorized into a "good prognosis group" and a "poor prognosis group" according to relevant efficacy criteria. The entire dataset will then be randomly divided into a training set (70%) and a test set (30%) following a 7:3 ratio.

03

Conditions studied

  • Tinnitus

Browse trials for

Keywords

  • acupuncture
  • moxibustion
  • tinnitus
  • fNIRS
  • machine learning
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bilateral tinnitus that meets the diagnostic criteria for chronic subjective tinnitus.
  • Male and female, aged between 18 and 60 years.
  • Right-handed subjects who are able to comply with the study protocol and sign written .
  • Not participating in other clinical trials concurrently.

Exclusion criteria

Exclusion Criteria:

  • Participants with objective tinnitus.
  • Participants have nervous system diseases or neuropsychiatric diseases that can significantly affect brain blood oxygen metabolism assessed by fNIRS.
  • Participants with severe cardiovascular and cerebrovascular diseases, malignant liver and kidney diseases, and other serious diseases.
  • Participants have any for acupuncture (such as a bleeding tendency).
  • Pregnant or lactating women.
  • Participants have received tinnitus treatment with drugs or other therapies in the last four weeks.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    The acupuncture group

    Subjects in the acupuncture group will undergo acupuncture treatment, which is administered 3 times a week for 4 weeks.

    Procedure: acupuncture

Interventions

  • Procedureacupuncture

    Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36 (Zusanli ), KI3 (Taixi), and etc.

06

What researchers measure

Primary outcomes

  1. Change in resting-state functional connectivity (RSFC)

    RSFC will be measured by functional near-infrared spectroscopy (fNIRS).

    Time frame: at baseline (pre-treatment), after 4-week treatment

  2. Change in hemoglobin signals

    Hemoglobin signals will be measured by functional near-infrared spectroscopy (fNIRS).

    Time frame: at baseline (pre-treatment), after 4-week treatment

  3. Change in Tinnitus Severity Grading

    Tinnitus Severity Grading is based on relevant expert consensus.

    Time frame: at baseline (pre-treatment), after 4-week treatment

Secondary outcomes

  1. Change in Tinnitus Handicap Inventory score

    Tinnitus Handicap Inventory contains 25 items, each valued at 0-4 points. A larger score indicates a more severe degree of tinnitus.

    Time frame: at baseline (pre-treatment), after 4-week treatment

  2. Change in average pure-tone threshold

    The average pure-tone threshold will be assessed by pure-tone audiometry.

    Time frame: at baseline (pre-treatment), after 4-week treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Aug 2026, 27 months later.

Of 134 non-industry interventional studies with no phase under Tinnitus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 27 months is above that.

Counting every sponsor, half of 153 studies reached it within 17 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Apr 15, 2024
StartEst.
May 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06364670
Lead sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Responsible party
Hantong Hu (M.D., The Third Affiliated hospital of Zhejiang Chinese Medical University) — Principal investigator
First posted
Apr 15, 2024
Start date
May 2024 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 15, 2024

Study contacts

Xiaohan Huang, M.M
Contact
1215360683@qq.com
18334334738 ext. 86
Hantong Hu, M.D
principal investigator · The Third Affiliated hospital of Zhejiang Chinese Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion